EFPIA anticounterfeiting pilot success could see industry recognise parallel traders as part of supply chain
This article was originally published in Scrip
Executive Summary
Mass serialisation is a viable way of strengthening the supply chain and protecting against counterfeit medicines, a pilot launched by the European Federation of Pharmaceutical Industries and Associations (EFPIA) has shown. Furthermore, roll-out of such a verification system could prompt industry to recognise parallel traders as part of the supply chain.
You may also be interested in...
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.